Aptuit Acquisition of Evotec AG CPD Business Completes Unique Global API Development Supply Chain

Aptuit, Inc. today announced that it has completed the acquisition
of the Chemical and Pharmaceutical Development (CPD) business of
Evotec, which integrates an active pharmaceutical ingredient (API)
facility in Oxford, England and a well-established and
recently-expanded parenteral (injectable vials) fill/finish facility
in Glasgow, Scotland into Aptuit´s global network. The integration of
these development and small scale manufacturing facilities in Europe
completes a unique global API supply chain where small scale
development takes place in the US and Europe with commercial scale
undertaken in new state of the art facilities in India. Aptuit brings
this service to its current client base of more than 750
pharmaceutical innovators.

"Over the past 18 months we´ve assembled by strategic acquisitions
the core competencies that are key to reducing the time and cost
burdens of drug development for our customers, and that also build on
our commitment to operate an efficient, integrated global network.
This particular acquisition is an important building block for Aptuit
as we move toward completing that network," said Michael A. Griffith,
Chief Executive Officer and Founder of Aptuit. "As the overall life
science industry evolves, we are continuously evaluating the ways in
which the drug development process must change and improve, and
executing forward-looking deals and partnerships that are beneficial
to our customers now and for the life of their products."

Griffith continued, "The commitment to be a global force and
provide full service in the US, Europe and Asia requires foresight and
discipline in anticipating the needs of the market, the ability to
attract, train and retain talent and build an infrastructure that best
meets those needs of our many and diverse clients continues to be the
focus of our attention as we constantly strive for improvements in the
drug development process. We also recognize that technology and the
ability to capture, store, analyze and present data in paperless
business transactions will be a prerequisite for companies like ours
in the future and we continue to actively invest in those resources
across our network.

In addition, Paul McGee (formerly Evotec´s Senior Vice President
of Chemical Development in Oxford, England), who will head the
business in Oxford commented, "I am truly impressed by the positive
response and interest by existing and prospective clients in the
capabilities Aptuit is assembling to improve the drug development
process and we have already made several proposals to clients jointly
with other parts of the Aptuit network and I am also delighted to
continue working on the exciting portfolio of products Evotec is
developing through the long term supply agreement established between
the two companies."

Since the acquisition of Evotec´s CPD business was announced,
Aptuit has worked to align:

-- The CPD business with its existing solid-state chemistry,
formulation and drug product manufacturing businesses, with a
critical part of which is Aptuit´s solid-state chemistry
center of excellence in West Lafayette (Indiana);

-- The small molecule API development labs, kilo labs and pilot
plants in Europe into Aptuit´s global API network with
existing operations in Harrisonville (Missouri), Kansas City
(Missouri) and Hyderabad (India), positioning Aptuit to
provide drug substance development, scale-up and manufacturing
capabilities in all three major pharmaceutical geographies;
and

-- The CPD business´ clinical scale parenteral fill/finish,
including two lyophilization suites, with Aptuit´s existing
fill/finish and lyophilization capabilities in Kansas City,
establishing substantial capacity in one of the fastest
growing and most lively sectors of drug development.

"Positioning our Chemical and Pharmaceutical Development business
supports the needs of our biotechnology and pharmaceutical innovator
clients in this sector by giving them access to a mature suite of
capabilities within a company that can support specific needs across
the drug development continuum," said Jorn Aldag, President & Chief
Executive Officer of Evotec.

About Evotec

Evotec is a leader in the discovery and development of novel small
molecule drugs. Both through its own discovery programs and through
research collaborations, the Company is generating the highest quality
research results to its partners in the pharmaceutical and
biotechnology industries.

In proprietary projects, Evotec specializes in finding new
treatments for diseases of the Central Nervous System. Evotec has
three programs in clinical development: EVT 201, a partial positive
allosteric modulator (pPAM) of the GABA(A) receptor complex for the
treatment of insomnia, EVT 101, a subtype selective NMDA receptor
antagonist for the treatment of Alzheimer´s disease and/or pain, and
EVT 302, a MAO-B inhibitor in development for smoking cessation.

www.evotec.com

About Aptuit

Aptuit is a global company focused on streamlining and supporting
the drug development process for biotechnology and pharmaceutical
innovators. The company was founded by a group of industry experts
with extensive market experience who have a track record of building a
similar, highly successful company through acquisitions and
investment. Aptuit provides a comprehensive suite of product
development services and competencies to more than 600 biotechnology
and large, fully integrated pharmaceutical innovators worldwide.
Following the acquisition of the CPD business, Aptuit will have 2,680
employees across 18 global facilities, including the
recently-announced formation of Aptuit Laurus (India). Aptuit´s
mission is to engineer a better drug development process, and is
partnered with Welsh, Carson, Anderson & Stowe, one of the world´s
largest private equity investors. For more information about Aptuit,
please visit www.aptuit.com.